Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Revenue (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Revenue for 16 consecutive years, with -$21000.0 as the latest value for Q4 2025.

  • Quarterly Revenue fell 106.84% to -$21000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $508000.0 through Dec 2025, down 63.87% year-over-year, with the annual reading at $508000.0 for FY2025, 63.87% down from the prior year.
  • Revenue hit -$21000.0 in Q4 2025 for Perspective Therapeutics, down from $144000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $2.9 million in Q1 2022 to a low of -$3.8 million in Q4 2023.
  • Historically, Revenue has averaged $1.2 million across 5 years, with a median of $1.7 million in 2022.
  • Biggest five-year swings in Revenue: soared 108.07% in 2024 and later crashed 106.84% in 2025.
  • Year by year, Revenue stood at $2.8 million in 2021, then tumbled by 39.03% to $1.7 million in 2022, then tumbled by 321.61% to -$3.8 million in 2023, then surged by 108.07% to $307000.0 in 2024, then plummeted by 106.84% to -$21000.0 in 2025.
  • Business Quant data shows Revenue for CATX at -$21000.0 in Q4 2025, $144000.0 in Q3 2025, and $171000.0 in Q2 2025.